|
|
Volumn 339, Issue 6116, 2013, Pages 130-
|
|
Approval of novel TB drug celebrated - With restraint
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEDAQUILINE;
QUINOLINE DERIVATIVE;
TUBERCULOSTATIC AGENT;
DRUG;
TUBERCULOSIS;
DRUG APPROVAL;
DRUG SENSITIVITY;
FOOD AND DRUG ADMINISTRATION;
HEART RHYTHM;
HUMAN;
MONOTHERAPY;
MULTIDRUG RESISTANT TUBERCULOSIS;
MYCOBACTERIUM TUBERCULOSIS;
NONHUMAN;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SHORT SURVEY;
SIDE EFFECT;
CLINICAL TRIAL (TOPIC);
DRUG COMBINATION;
DRUG EFFECT;
ENZYMOLOGY;
MICROBIOLOGY;
MULTIDRUG RESISTANCE;
NOTE;
UNITED STATES;
ANTITUBERCULAR AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG RESISTANCE, MULTIPLE, BACTERIAL;
DRUG THERAPY, COMBINATION;
HUMANS;
MYCOBACTERIUM TUBERCULOSIS;
QUINOLINES;
TUBERCULOSIS, MULTIDRUG-RESISTANT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84872131305
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.339.6116.130 Document Type: Short Survey |
|
Times cited : (143)
|
|
References (0)
|
